Conclusion”Comparsion of the Bieoquvalence of Generic Versus Branded Clozapine”
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Clozapine, the first atypical antipsychotic, has been marketed in the United States since 1989. Its usage has been restricted to those patients with persistent psychotic or bipolar disorder who are considered treatment resistant and who are intolerant of standard antipsychotic therapies. Clozapine has also been found to be the least likely of the antipsychotics to worsen previously diagnosed tardive dyskinesia.1 With the expiration of Novartis’s patent for Clozaril in 1998, generic products have now begun to be marketed.